Je was op zoek naar: okluzivni (Sloveens - Engels)

okluzivni povoj
occlusive dressing

okluzivni ali neokluzivni);
occlusive or not occlusive);

okluzivni zavoji niso priporočeni.
occlusive dressings are not recommended.

vaskularni okluzivni dogodki so se pojavili pri 44 od teh 132 bolnikov.
vascular occlusive events occurred in 44 of these 132 patients.

okluzivni obliži se s primernim povojem 6 ur držijo v stiku s kožo.
the occlusive patches are held in contact by a suitable dressing for 6 hours.

preskusni pogoji (vključno z vrsto povoja: okluzivni ali neokluzivni),
test conditions (including the type of dressing: occlusive or not-occlusive),

o veno-okluzivni bolezni so poročali v razponu med 3,9 in 15,4 %.
vod was reported with a range between 3.9% and 15.4%.

po injiciranju zdravila zamenjajte rokavice, preden namestite okluzivni povoj na spremembe, v katere ste injicirali.
after administration, change gloves prior to applying occlusive dressings to injected lesions.

gel naj se suši približnos 10 minut, nato pa se na mesto zdravljenja namesti okluzivni povoj, ki ne prepušča svetlobe.
the gel should be allowed to dry for approximately 10 minutes, before an occlusive light-tight dressing is placed over the treatment site.

na zadnji del boka tretiranih živali se pritrdi okluzivni obliž ali posodica z 0,5 ml preskusne snovi v največji nedražilni koncentraciji.
an occlusive patch or chamber containing 0,5 ml of the test substance is applied, at the maximum non-irritant concentration, to the posterior of the flank of treated animals.

zdravila regranex ne sme uporabljati skupaj s povojem, ki preprečuje stik rane z zrakom ali vodo (okluzivni povoj).
do not use air- or water-tight (occlusive) dressings on the wound.

Če je primerno, se okluzivni obliž ali gaza, ki vsebuje samo nosilec, nanese tudi na sprednji netretirani bok tretiranih in tudi kontrolnih živali.
when relevant, an occlusive patch or chamber with vehicle only is also applied to the anterior untreated flank of both treated and control animals.

na zadnji del netretiranega boka tretiranih in kontrolnih živali se nanese okluzivni obliž ali gaza, vsebujoča ustrezno količino preskusne snovi pri najvišji koncentraciji, ki še ne povzroča draženja.
an occlusive patch or chamber containing the appropriate amount of test substance is applied, at the maximum non-irritant concentration, to the posterior untreated flank of treated and control animals.

na zadnji del netretiranega boka tretiranih in kontrolnih živali se nanese okluzivni obliž ali gaza, vsebujoča ustrezno količino preskusne snovi pri najvišji koncentraciji, ki še ne povzroča draženj a.
an occlusive patch or chamber containing the appropriate amount of test substance is applied, at the maximum non-irritant concentration, to the posterior untreated flank of treated and control animals.

v preskušanju 2. faze so se arterijski in venski okluzivni neželeni učinki pojavili pri 23 % bolnikov (pogostnosti v povezavi z zdravljenjem).
in the phase 2 trial, arterial and venous occlusive adverse reactions have occurred in 23% of patients (treatment-emergent frequencies).

v preskušanjih 2. faze so se resni arterijski in venski okluzivni neželeni učinki pojavili pri 18 % bolnikov (pogostnosti v povezavi z zdravljenjem).
in the phase 2 trial, serious arterial and venous occlusive adverse reactions occurred in 18% of patients (treatment-emergent frequencies).

preglednica 10 vaskularni okluzivni prvi neželeni učinki pri bolnikih s cp-kml, ki so dosegli mcyr pri 45 mg ali 30 mg (ekstrakcija podatkov 7. aprila 2014)
table 10 vascular occlusive first adverse events in cp-cml patients who achieved mcyr at 45 mg or 30 mg (data extraction 7 april 2014)

informacije o pomembnih neželenih učinkih, za katere se priporoča spremljanje in/ali prilagajanje odmerka, kot je opisano v povzetku glavnih značilnosti zdravila: pankreatitis, povečane ravni amilaze in lipaze, mielosuppresija, nenormalnosti testa delovanja jeter, krvavitev, odpoved srca/disfunkcija levega prekata, vaskularni okluzivni dogodki in hipertenzija.
information on important adverse reactions for which monitoring and/or dose adjustment are recommended as outlined in the smpc: pancreatitis, increased amylase and lipase levels, myelosuppression, liver function test abnormalities, haemorrhage, cardiac failure/left ventricular dysfunction, vascular occlusive events and hypertension.